These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20936874)

  • 1. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
    Kularatne SA; Venkatesh C; Santhapuram HK; Wang K; Vaitilingam B; Henne WA; Low PS
    J Med Chem; 2010 Nov; 53(21):7767-77. PubMed ID: 20936874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
    Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
    Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
    J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
    Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
    Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
    J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
    Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer.
    Martin SE; Ganguly T; Munske GR; Fulton MD; Hopkins MR; Berkman CE; Black ME
    Bioconjug Chem; 2014 Oct; 25(10):1752-60. PubMed ID: 25157916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
    Ivanenkov YA; Machulkin AE; Garanina AS; Skvortsov DA; Uspenskaya AA; Deyneka EV; Trofimenko AV; Beloglazkina EK; Zyk NV; Koteliansky VE; Bezrukov DS; Aladinskaya AV; Vorobyeva NS; Puchinina MM; Riabykh GK; Sofronova AA; Malyshev AS; Majouga AG
    Bioorg Med Chem Lett; 2019 May; 29(10):1246-1255. PubMed ID: 30904185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
    Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
    Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
    Harada N; Kimura H; Ono M; Saji H
    J Med Chem; 2013 Oct; 56(20):7890-901. PubMed ID: 24063417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (
    Duan X; Liu F; Kwon H; Byun Y; Minn I; Cai X; Zhang J; Pomper MG; Yang Z; Xi Z; Yang X
    J Med Chem; 2020 Apr; 63(7):3563-3576. PubMed ID: 32207938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
    Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
    J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine-based asymmetric urea ligand for prostate carcinoma: Tuning biological efficacy through in silico studies.
    Sengupta S; Krishnan MA; Pandit A; Dudhe P; Sharma R; Chelvam V
    Bioorg Chem; 2019 Oct; 91():103154. PubMed ID: 31404798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
    Akinboye ES; Rosen MD; Bakare O; Denmeade SR
    Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
    Roy J; Nguyen TX; Kanduluru AK; Venkatesh C; Lv W; Reddy PV; Low PS; Cushman M
    J Med Chem; 2015 Apr; 58(7):3094-103. PubMed ID: 25822623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
    Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
    Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
    Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A
    Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.